Effectiveness trial of bucindolol and Toprol-XL for prevention of symptomatic AF
GENETIC-AF: A genotype-directed comparative effectiveness trial of bucindolol and Toprol-XL for prevention of symptomatic AF/AFL in patients with heart failure. The goal of this study is to demonstrate the superiority of pharmacogenetically targeted bucindolol compared to metoprolol for the prevention of symptomatic AF/AFL in a genotype-defined B1389Arg/Arg HFREF population at high risk of AF/AFL recurrence.
Questions: Call Mary Soltau 303-703-2191 or Rebecca Wimmer 303-715-2275